Strategic Initiative

Slingshot members are tracking this corporate initiative:

Clovis Oncology (CLVS) and Immunomedics (IMMU) Announce Collaboration in Metastatic Triple-Negative Breast and Urothelial Cancers

Source Link:: https://immunomedics.com/2018/clovis-oncology-and-immunomedics-announce-planned-clinical-collaboration-to-study-combination-therapies-in-metastatic-triple-negative-breast-and-urothelial-cancers/

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CLVS

100%

IMMU

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Companies to Start Phase 1/2 Study to Evaluate the Combination of Rubraca (Rucaparib) and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial Cancer

https://immunomedics...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Jun 03, 2018

Projected Implementation:

Q2, 2018

Relevance Tracked Until:

Q3, 2018

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Triple-negative Breast Cancer, Urothelial Cancer, Rubraca, Rucaparib, Sacituzumab Govitecan